January 15, 2025 | Vensana Capital® Press Releases

Vensana Capital Closes $425 Million Fund III to Back Breakthrough Medical Technology Companies

21

Novel FDA PMA & de novo 510k approvals

60

U.S. Commercial Product Launches

40

Level I Clinical Trials

32

Strategic Financings

31

Exits by IPO or M&A